Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-226

this is from the orginal CHF 15 12 2020
"Despite significant reduction in
the pre-specified endpoint of cardiac death, there was no reduction in recurrent non-fatal
decompensated heart failure events, which was the trial’s primary endpoint. This suggests that
rexlemestrocel-L reduces mortality by mechanisms that are distinct from those of existing drugs that
reduce hospitalization rates but do not significantly impact cardiac mortality. "

this is from today

"Patients who received rexlemestrocel-L had a 68% reduction in the rate ofrecurrent hospitalizationsfrom non-fatal heart attacks or strokes comparedwith controls, with a hospitalization rate of 1.90 per 100 patient years offollow-up in the rexlemestrocel-L arm versus 5.95 per 100 patient-years offollow-up in the control arm (p=0.0002)".

If this is correct??!! This is totally contrary to what the initial data said back in Decemeber. 68% against nothing meaningful? ( of course wording is slightly different but does then change the failure to a pass in primary endpoint)
we have got some great analysis out there, please explain because this seem very clear cut amazing?!